A randomized, controlled trial of linopirdine in the treatment of Alzheimer's disease

Canadian Journal of Neurological Sciences

Volumn 24, Issue 2, 1997, Pages 140-145

  Rockwood, Kenneth ^a,g   Beattie, B Lynn ^b   Eastwood, M Robin ^c   Feldman, Howard ^b   Mohr, Erich ^d   Pryse Phillips, William ^e   Gauthier, Serge ^f  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLINERGIC RECEPTOR STIMULATING AGENT; LINOPIRDINE; LIVER ENZYME; PLACEBO;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 0030956507     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S031716710002148X     Document Type: Article

References (42)

1. Canadian Study of Health and Aging Working Group. Canadian Study of Health and Aging: methods and prevalence of dementia. Can Med Assoc J 1994; 150: 899-914.
2. Rockwood K, Stadnyk K. the prevalence of dementia in the elderly: a review. Can J Psychiatry 1994; 39: 253-257.
3. Hay JW, Ernst RL. The economic cost of Alzheimer's disease. Am J Public Health 1987; 77: 1169-1175.
4. Ostbye T, Crosse E. Net economic cost of dementia in Canada. Can Med Assoc J 1994; 151: 1457-1564.
5. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 268: 2546-2565.
6. Farlow M, Gracon SJ, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1991; 268: 2564-2565.
7. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind placebo-controlled multicentre study of tacrine for Alzheimer's disease. N Engl J Med 1992; 327: 1253-1259.
8. Eagger SA, Levy R, Sahakiar RJ. Tacrine in Alzheimer's disease. Lancet 1991; 337: 989-992.
9. Chatellier G, Lacomble ZL. Tacrine and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Br Med J 1990; 300: 495-499.
10. Guathier S, Bouchard R, Lamontagne A, et al. Tetrahydroaminoacradine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. N Engl J Med 1990; 322: 1272-1276.
11. Mohr E, Schlegel J, Iabbrini G, et al. Clonidine treatment of Alzheimer's disease. Arch Neurol 1989; 46: 376-378.
12. Parnetti L, Senin U, Carosi M, Baasch H. Mental deterioration in old age: results of two multicentre, clinical trials with nimodipine. Clin Ther 1993; 15: 394-406.
13. Saletu B, Paulus E, Linzmayer L, et al. Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacol (Berl) 1995; 117: 385-395.
14. Cutler NR, Havby J, Kay AD, et al. Evaluation of zimeldine in Alzheimer's disease: cognitive and biochemical markers. Arch Neurol 1985; 42: 744-748.
15. Schneider LS, Olin JT. Overview of clinical trials of hydergine in dementia. Arch Neurol 1994; 51: 787-798.
16. Cook L, Nickolson VJ, Steinfels GF, et al. Cognition enhancement by the actelycholine releaser DUP 996. Drug Develop Res 1990; 19: 301-314.
17. Nickolson VJ, Tam SW, Myers MJ, Cook L. DuP 996 (3,3-Bis(4-Pyrindinylmethyl)-1-Pheylindolin-2-One) enchances the stimulus-induced release of acetylcholine from rat brain in vitro and in vivo. Drug Develop Res 1990; 19: 285-300.
18. DeNoble VJ, DeNoble KF, Spencer KR, et al. Comparison of DuP 996, with physostigmine, THA and 3,4-DAP on hypoxia-induced amnesia in rats. Pharmacol Biochem Behav 1990; 36: 957-961.
19. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 149: 1356-1364.
20. Kraemer HC, Thiemann S. How many subjects? Statistical Power Analysis in Research. Newbury Park, CA: Sage, 1987.
21. Erzigkeit H. The SKT - a short cognitive performance test as an instrument for the assessment of clinical efficacy of cognitive enhancers. In: Bergner W, Reisberg B, eds. Diagnosis and Treatment of Senile Dementia. Heidelberg: Springer, 1989.
22. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 1975; 12: 189-195.
23. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 176-186.
24. Baumgarten M, Becker R, Gauthier S. Validity and reliability of the dementia Behaviour Disturbance Scale. J Am Geriatric Soc 1990; 38: 221-226.
25. American Psychiatric Association. Diagnostic and Statistical Manual, 3rd ed., Revised. Washington: American Psychiatric Association, 1987.
26. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NlNCDS-ADRADA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
27. Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol 1975; 32; 632-637.
28. SAS Institute Inc. SAS/STAT Ser's Guide, Version 6, 4th ed. Cary, NC: SAS Institute Inc, 1989.
29. Mohr E, Feldman H, Gauthier S. Canadian guidelines for the development of antidementia therapies: a conceptual summary. Can J Neurol Sci 1995; 22: 62-71.
30. Rockwood K. Use of global assessment measures in dementia drug trials. J Clin Epidemiol 1994; 47: 101-103.
31. Gill TM, Feinstein AR. A critical appraisal of the quality of life measurements. JAMA 1994; 272: 619-626.
32. Howard K, Rockwood K. Quality of life in Alzheimer's disease. Dementia 1995; 6: 113-116.
33. Rockwood K, Stolee P, Howard K, Mallery L. The use of Goal Attainment Scaling in an anti-dementia drug trial. Neuroepidemiology 1996; 15: 330-338.
34. Davis KL, Powchik P. Tacrine. Lancet 1995; 345: 625-630.
35. Pomponi M, Giocobini E, Brufani M. Present state and future development of the therapy of Alzheimer disease. Aging 1990; 2: 125-153.
36. O'Connor DW, Pollitt PA, Hyde JB, et al. The reliability and validity of the Mini-Mental State in a British community survey. J Psychiat Res 1989; 23: 87-96.
37. Brayne C, Calloway P. The association of education and socioeconomic status with the Mini-Mental State Examination and the clinical diagnosis of dementia in elderly people. Age Ageing 1990; 19: 91-96.
38. Gagnon M, Letenneur L, Dartigues J-F, et al. Validity of the Mini-Mental State Examination as a screening instrument for cognitive impairment and dementia in French elderly community residents. Neuroepidemiology 1990; 9: 143-150.
39. Uhlmann FR, Larson EB. Effect of education on the Mini-Mental State Examination as a screening test for dementia. J Am Geriartr Soc 1991; 41: 1886-1892.
40. Jagger C, Clarke M, Anderson J. Screening for dementia - a comparison of two tests using receiver operating characteristic (ROC) analysis. Int J Geriatr Psychiatry 1992; 7: 659-665.
41. Ritchie K, Fuhrer R. A comparitive study of the performance of screening tests for senile dementia using receiver operating characteristics analysis. J Clin Epidemiol 1992; 45: 627-637.
42. Kaufmann L, Rousseeuw P. Finding Groups in Data. An Introduction to Cluster Analysis. New York: Wiley, 1990.